Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...

The study is led by the university’s psychiatry, psychology, and clinical and translational science associate professor Dr ...

Cipla received approval from India's Central Drugs Standard Control Organisation to distribute and market Afrezza inhalation ...

However, the drug store & retail pharmacies segment held the largest share in 2019, contributing to nearly two-thirds of the global rapid acting insulin market, owing to availability of rapid ...

Ketamine has "shown promise" in the rapid treatment of major depression and suicidal thoughts, a US study says. Ketamine has a reputation as a party drug but is licensed as an anaesthetic.